Scarica l'app Stockscreener
171.89
2.73%
4.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Why Axsome Therapeutics Inc. stock could outperform in 20252025 Market Overview & Verified Chart Pattern Signals - ulpravda.ru
Will Axsome Therapeutics Inc. stock reach all time highs in 2025July 2025 Drop Watch & Daily Price Action Insights - ulpravda.ru
How interest rate cuts could boost Axsome Therapeutics Inc. stock2025 Pullback Review & Weekly Top Performers Watchlists - ulpravda.ru
Can Axsome Therapeutics Inc. (19X) stock hold up in economic slowdown2025 Historical Comparison & Expert Approved Momentum Ideas - ulpravda.ru
How Axsome Therapeutics Inc. stock reacts to Fed rate cutsBreakout Watch & Fast Gain Swing Alerts - ulpravda.ru
Why Axsome Therapeutics Inc. stock is rated strong buyJuly 2025 Reactions & Smart Allocation Stock Tips - ulpravda.ru
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - MarketBeat
Morgan Stanley Downgrades Axsome Therapeutics to Equal Weight From Overweight, Adjusts PT to $204 From $196 - MarketScreener
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Morgan Stanley downgrades Axsome stock after 23% rally, raises price target - Investing.com Canada
Axsome therapeutics CEO sells $23.8m in shares By Investing.com - Investing.com UK
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) CEO Sells 29,450 Shares of Stock - MarketBeat
Herriot Tabuteau Sells 31,261 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Equities Analysts Set Expectations for AXSM Q2 Earnings - MarketBeat
UBS Adjusts Price Target on Axsome Therapeutics to $248 From $163, Maintains Buy Rating - MarketScreener
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
H.C. Wainwright raises Axsome Therapeutics stock price target on FDA priority review - Investing.com Canada
Axsome Therapeutics (AXSM) Stock Analysis: Revenue Growth Soars Amid Biotech Innovations - DirectorsTalk Interviews
AXSM: HC Wainwright & Co. Raises Price Target to $200 and Mainta - GuruFocus
Stanley Laman Group Ltd. Makes New $2.13 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics - The Pharma Letter
Axsome Therapeutics Insider Sold Shares Worth $6,206,969, According to a Recent SEC Filing - MarketScreener
Why Axsome Therapeutics (AXSM) Is Up 17.5% After Dual FDA Boosts For AXS-05 And AXS-12 – And What's Next - Yahoo Finance
Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12 - Yahoo Finance
Axsome therapeutics director Saad sells $6.2m in shares By Investing.com - Investing.com Canada
Mark Saad Sells 37,577 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Glaukos (GKOS) - The Globe and Mail
A Comprehensive Guide To Axsome: Unlocking The Potential Of Innovative Therapeutics- - shababeek.org
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation - Finviz
Truist Securities reiterates Buy rating on Axsome Therapeutics stock By Investing.com - Investing.com Canada
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar? - Yahoo Finance
Deutsche Bank Raises Price Target on Axsome Therapeutics to $223 From $186, Keeps Buy Rating - MarketScreener
FDA grants Axsome’s AXS-05 sNDA priority review designation - The Pharma Letter
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation - ts2.tech
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug - ts2.tech
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX) - The Globe and Mail
Axsome Advances AXS-12 Toward NDA Filing for Narcolepsy - The Globe and Mail
Axsome (AXSM) Stock; Climbs Nearly 23% After FDA Accelerates Alzheimer’s Review - CoinCentral
Moody Aldrich Partners LLC Trims Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing - ts2.tech
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease agitation - MSN
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review - ts2.tech
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Nigeria
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 - The Globe and Mail
Axsome Therapeutics Stock Skyrockets: What’s Next? - StocksToTrade
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation - ts2.tech
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? - AOL.com
Key Takeaways - StocksToTrade
Axsome’s Surprising Surge: What’s Next ? - timothysykes.com
From Haiti to Wall Street to Big Pharma: Herriot Tabuteau is on a $6B mission to heal the brain - AOL.com
Axsome Therapeutics price target raised to $217 from $202 at Mizuho - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com Nigeria
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing - ts2.tech
Axsome Therapeutics says AXS-12 NDA submission on track for January - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock - Investing.com
Axsome Therapeutics Stock Surge Analysis - timothysykes.com
Axsome Therapeutics: Late-Stage CNS Pipeline and Regulatory Tailwinds Support Buy Rating - TipRanks
Mizuho raises Axsome Therapeutics stock price target on regulatory progress - Investing.com
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):